Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $7.88 Million - $11.3 Million
273,400 New
273,400 $7.88 Million
Q1 2022

May 17, 2022

BUY
$35.46 - $54.12 $3.77 Million - $5.75 Million
106,300 Added 292.84%
142,600 $7.25 Million
Q4 2021

Feb 15, 2022

SELL
$30.74 - $49.16 $24.5 Million - $39.2 Million
-798,000 Reduced 95.65%
36,300 $1.72 Million
Q3 2021

Nov 16, 2021

BUY
$31.4 - $69.84 $24.2 Million - $53.9 Million
772,000 Added 1239.17%
834,300 $27.5 Million
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $2.07 Million - $3.28 Million
50,600 Added 432.48%
62,300 $3.94 Million
Q4 2020

Feb 17, 2021

SELL
$30.79 - $57.2 $372,559 - $692,120
-12,100 Reduced 50.84%
11,700 $669,000
Q3 2020

Nov 17, 2020

BUY
$25.89 - $33.65 $168,285 - $218,725
6,500 Added 37.57%
23,800 $718,000
Q2 2020

Aug 17, 2020

BUY
$24.8 - $38.49 $429,040 - $665,877
17,300 New
17,300 $565,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.89B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.